▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3962 by analyst upside · 2026-11-12
JNJ
Johnson & Johnson
Healthcare · Market Cap $675B · P/E 42.6x
ANALYST PRICE TARGET
-0.4%
implied upside to consensus target
Current Price $280.41
Consensus Target $279.41
Bull Target $320.0
Bear Target $190.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
11
Hold
6
Sell
0
52-Week Low $193.07
52-Week High $283.25
YTD Return +37.4%
FUNDAMENTALS
Market Cap $675B
P/E Ratio (TTM) 42.6x
Forward P/E 24.1x
EPS (TTM) $6.58
PEG Ratio 3.16
Dividend Yield 1.91%
Revenue (TTM) $99.3B
Profit Margin 16.2%
52-WEEK RANGE
52-Week Low $193.07
52-Week High $283.25
Current Price $280.41
Bear Target $190.0
Bull Target $320.0
● Now $280.41 ● Target $279.41
TRADING DATA
Avg Volume 7.0M
YTD Return +37.4%
Analyst Count 22
Consensus Buy
Upside to Target -0.4%
Last Updated 2026-11-12

ANALYST SUMMARY

Johnson & Johnson (JNJ) is currently trading at $280.41 with a Wall Street consensus price target of $279.41, which is 0.4% below the current price over the next 12 months. 22 analysts currently cover JNJ, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $320.0, while the most cautious has a target of $190.0.

JNJ operates in the Healthcare sector with a market capitalisation of $675B. The stock is up 37.4% year-to-date and is currently trading near the upper end of its 52-week range of $193.07 – $283.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for JNJ, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wells Fargo - Reiterated
Overweight → Overweight 2026-10-16 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-10-15 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-10-14 29% win rate (7 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-10-14 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-10-14 Building track record
Guggenheim reit
Buy → Buy 2026-10-07 62% win rate (8 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-10-06 Building track record
Citigroup - Reiterated
Buy → Buy 2026-10-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
24/30
Consensus clarity
21/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →